KRAS and squamous cell lung carcinoma: PDTOs replicated clinically relevant drug responses such as Kirsten rat sarcoma viral oncogene homolog (KRAS)‐mutant models showing mitogen‐activated protein kinase kinase (MEK) inhibitor sensitivity and synergistic fibroblast growth factor receptor (FGFR)/MEK inhibition in FGFR1‐amplified lung squamous cell carcinomas.